Bailard’s Zevra Therapeutics ZVRA Stock Holding History

Bailard’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$137K	Buy	14,700 +1,800	+14%	+$16.2K	﹤0.01%	712
2025 Q4	$116K	Buy	+12,900	New	+$122K	﹤0.01%	735

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Bailard's ZVRA Position: Q1 2026 in Review

Bailard increased its Zevra Therapeutics (ZVRA) stake by 14% in Q1 2026, buying an estimated $16.2K and bringing the position to 14,700 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #712.

Bailard first reported a position in ZVRA in Q4 2025 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Bailard held 14,700 shares of Zevra Therapeutics worth $137K as of Q1 2026.
Bailard bought 1,800 Zevra Therapeutics shares in Q1 2026, an estimated $16.2K.
Zevra Therapeutics made up ﹤0.01% of Bailard's portfolio in Q1 2026, its #712 holding.
Bailard first reported a position in Zevra Therapeutics in Q4 2025 and has held it in 2 quarters since.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.